The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Development of an artificial intelligence algorithm for adjuvant chemotherapy based on a nationwide registry of patients with gastric cancer by the Japanese Gastric Cancer Association (JGCA).
 
Yasuhide Yamada
Honoraria - Boehringer Ingelheim; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst)
 
Ami Kamada
Employment - IBM
 
Yoshinori Kabeya
Employment - IBM
 
Sumito Yoshida
No Relationships to Disclose
 
Hitoshi Harada
No Relationships to Disclose
 
Naoki Urakawa
No Relationships to Disclose
 
Shingo Kanaji
No Relationships to Disclose
 
Yuma Nakamura
Employment - IBM
 
Kengo Nagashima
Consulting or Advisory Role - Fujimoto; Kowa; Senju Pharmaceutical; Toray Industries
 
HIROYA TAKEUCHI
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical (Inst)
 
Yuichiro Doki
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly Japan; MSD; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Chugai Pharma; Daiichi Sankyo; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
 
Yuko Kitagawa
Honoraria - Asahi Kasei; ASKA Pharmaceutical Co., Ltd.; AstraZeneca Japan; Bristol-Myers Squibb K.K.; Chugai Foundation for Innovative Drug Discovery Science; Chugai Pharma; DAIICHI SANKYO COMPANY, LIMITED; EA Pharma; Ethicon; Intuitive Surgical; Kaken Pharmaceutical; Miyarisan pharmaceutical; MSD K.K.; Nippon Covidien; Nippon Kayaku; Olympus; Ono Pharmaceutical; Otsuka; Shionogi; Smith & Nephew; Sysmex; Taiho Pharmaceutical; Toray Industries
Consulting or Advisory Role - Bristol-Myers Squibb K.K.; Ono Pharmaceutical
Research Funding - Asahi Kasei (Inst); Chugai Pharma (Inst); Eisai (Inst); Kaken Pharmaceutical (Inst); Kowa (Inst); Kyouwa Hakkou Kirin Co., Ltd. (Inst); Nippon Covidien (Inst); Otsuka (Inst); Otsuka (Inst); Sumitomo Pharma Co., Ltd. (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst); TSUMURA & CO. (Inst)
 
Yasuhiro Kodera
Honoraria - Abbvie; Amgen; Bristol Myers Squibb; Chugai Pharma; Covidien/Medtronic; Daiichi Sankyo; Lilly Japan; Miyarisan Pharmaceutical; MSD K.K; Nippon Kayaku; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical; Tsumura & Co.; Yakult Honsha
Consulting or Advisory Role - Daii Sankyo
Research Funding - abbott Japan (Inst); Abbvie (Inst); Bayer (Inst); Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); EA Pharma (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); Lilly Japan (Inst); Nippon Kayaku (Inst); Otsuka (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); TOA Pharmaceuticals (Inst); Tsumura & Co. (Inst)
 
Yoshihiro Kakeji
Honoraria - Taiho Pharmaceutical